Indirect protection in adults≥ 18 years of age from pediatric pneumococcal vaccination: a review
E Flem, C Mouawad, AA Palmu, H Platt… - Expert Review of …, 2024 - Taylor & Francis
Introduction Infant immunization programs using pneumococcal conjugate vaccines (PCVs)
have reduced the rates of pneumococcal disease through direct vaccine-induced protection …
have reduced the rates of pneumococcal disease through direct vaccine-induced protection …
[HTML][HTML] Pneumonia-Related Hospitalizations among the Elderly: A Retrospective Study in Northeast Italy
S Cocchio, C Cozzolino, P Furlan, A Cozza, M Tonon… - Diseases, 2024 - mdpi.com
Background: In both the elderly and children, pneumonia remains one of the leading causes
of hospitalization. This study aimed to assess the impact of pneumonia-related …
of hospitalization. This study aimed to assess the impact of pneumonia-related …
Effect of reduced two-dose (1+ 1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and …
Introduction This study aimed to assess the effect of a reduced dose regime (1+ 1) of PCV10
and PCV13 along with 3-dose regimes on pneumococcal vaccine-type (VT) carriage and …
and PCV13 along with 3-dose regimes on pneumococcal vaccine-type (VT) carriage and …
Incidence and mortality trends of acute gastroenteritis and pneumococcal disease in children following universal rotavirus and pneumococcal conjugate vaccination in …
P Juliao, A Guzman-Holst, V Gupta, C Velez… - Infectious Diseases and …, 2021 - Springer
Introduction Ecuador introduced routine infant rotavirus (RV) vaccination in 2008 and
pneumococcal conjugate vaccination (PCV) in 2011 to manage disease and mortality in …
pneumococcal conjugate vaccination (PCV) in 2011 to manage disease and mortality in …
Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact
J Nieto Guevara, A Guzman-Holst - Human Vaccines & …, 2021 - Taylor & Francis
Disease surveillance data are needed to monitor trends in disease activity, inform decision-
making in public health and evaluate disease prevention/control measures. The Sistema …
making in public health and evaluate disease prevention/control measures. The Sistema …
Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries
Abstract Background Pneumococcal conjugate vaccines (PCVs) provide strong direct
protection in children, while limited data are available on their indirect effect on mortality …
protection in children, while limited data are available on their indirect effect on mortality …
[HTML][HTML] Antiviral Activity of Angelica Tenuissima Nakai against Influenza A Virus
WJ Park, GS Bae, YH Han - Pathogens, 2024 - mdpi.com
The influenza A virus poses a serious threat to human health and is an important global
public health issue. The drugs currently used for treatment are becoming increasingly …
public health issue. The drugs currently used for treatment are becoming increasingly …
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece
JE Perdrizet, MH Rozenbaum, MJ Heffler - Infectious Diseases and …, 2024 - Springer
Abstract Introduction Most European infant national immunization programs (NIPs)
recommend pneumococcal conjugate vaccines (PCVs), which currently cover 10–15 …
recommend pneumococcal conjugate vaccines (PCVs), which currently cover 10–15 …
A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+ 1 …
A Maestri, SE Park, F Fernandes, ZL Li… - Human Vaccines & …, 2024 - Taylor & Francis
There is an ongoing burden of pneumococcal disease in children despite the use of
pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite …
pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite …
[HTML][HTML] Return on investment of 10-valent pneumococcal conjugate vaccine in Ecuador from 2010 to 2030
R Jimbo-Sotomayor, E Watts, L Armijos… - Value in Health …, 2022 - Elsevier
Objectives Ecuador introduced the pneumococcal conjugate vaccine in 2010. A recent time
series analysis has demonstrated the impact of 10-valent pneumococcal conjugate vaccine …
series analysis has demonstrated the impact of 10-valent pneumococcal conjugate vaccine …